Zomedica Corp Quarterly Balance Sheets Chart
Quarterly
|
Annual
Zomedica Corp Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||
| | ||||||||||||
| current assets | ||||||||||||
| cash and cash equivalents | 10,939,000 | 12,952,000 | 21,783,000 | 27,951,000 | 8,353,000 | 27,399,000 | 45,095,000 | 186,763,000 | 192,337,000 | 194,952,208 | 271,411,043 | 276,209,816 |
| available-for-sale securities | 72,023,000 | 77,545,000 | 84,424,000 | 102,522,000 | 112,698,000 | 87,693,000 | 74,200,000 | |||||
| trade receivables | 1,649,000 | 1,197,000 | 1,348,000 | 654,000 | 428,000 | 596,000 | 719,000 | 414,000 | 341,000 | 315,418 | 6,938 | 4,264 |
| inventory | 5,062,000 | 5,123,000 | 3,737,000 | 3,634,000 | 2,743,000 | 2,746,000 | 2,400,000 | 4,819,000 | 3,606,000 | 2,847,985 | 1,423,923 | 793,898 |
| prepaid expenses and deposits | 1,616,000 | 2,064,000 | 3,018,000 | 3,562,000 | 4,856,000 | 3,799,000 | 3,611,000 | 2,315,000 | 1,696,000 | 1,841,814 | 1,633,846 | 222,478 |
| other receivables | 780,000 | 1,001,000 | 1,084,000 | 1,302,000 | 1,085,000 | 1,268,000 | 1,078,000 | 315,000 | 470,000 | 450,081 | 258,359 | 268,501 |
| total current assets | 92,069,000 | 99,882,000 | 115,394,000 | 139,625,000 | 130,163,000 | 123,501,000 | 127,103,000 | 194,626,000 | 198,450,000 | 200,407,506 | 274,734,109 | 277,498,957 |
| property and equipment | 23,971,000 | 10,347,000 | 8,259,000 | 7,291,000 | 6,799,000 | 6,809,000 | 6,727,000 | 1,710,000 | 1,373,000 | 1,205,546 | 706,266 | 265,845 |
| right-of-use asset | 2,253,000 | 2,466,000 | 1,681,000 | 1,355,000 | 1,511,000 | 1,665,000 | 1,567,000 | 1,638,000 | 1,218,000 | 1,319,810 | 1,419,790 | 1,132,548 |
| goodwill | 61,580,000 | 61,580,000 | 73,774,000 | 63,979,000 | 63,979,000 | 63,979,000 | 64,230,000 | 43,288,000 | 43,288,000 | 43,287,765 | ||
| intangible assets | 54,802,000 | 55,364,000 | 56,928,000 | 48,071,000 | 48,433,000 | 41,799,000 | 42,778,000 | 32,097,000 | 32,439,000 | 33,519,560 | 473,966 | 373,851 |
| non current available-for-sale securities | 7,964,000 | 10,005,000 | 11,787,000 | 11,920,000 | 26,409,000 | 40,712,000 | 39,197,000 | |||||
| other assets | 819,000 | 822,000 | 852,000 | 265,000 | 265,000 | 265,000 | 265,000 | 265,000 | 265,000 | 265,000 | ||
| total assets | 243,701,000 | 253,197,000 | 275,052,000 | 274,778,000 | 279,598,000 | 279,610,000 | 282,299,000 | 275,478,000 | 277,990,000 | 280,399,293 | 277,502,151 | 280,352,284 |
| liabilities and shareholders’ equity | ||||||||||||
| current liabilities | ||||||||||||
| accounts payable and accrued liabilities | 6,676,000 | 7,668,000 | 5,598,000 | 6,144,000 | 7,419,000 | 6,698,000 | 6,244,000 | 3,491,000 | 3,109,000 | 3,225,348 | 4,464,874 | 3,095,203 |
| accrued income taxes | 66,000 | 65,000 | 114,000 | 74,000 | 233,000 | 187,000 | 41,000 | 41,000 | 217,000 | 239,924 | ||
| current portion of lease obligations | 847,000 | 916,000 | 679,000 | 641,000 | 641,000 | 641,000 | 578,000 | 523,000 | 422,000 | 414,695 | 407,278 | 302,112 |
| customer contract liabilities | 260,000 | 276,000 | 257,000 | 255,000 | 242,000 | 207,000 | 205,000 | 153,000 | 148,000 | 198,112 | ||
| other current liabilities | 159,000 | 107,000 | 92,000 | 96,000 | 62,000 | 78,000 | 58,000 | 266,000 | 222,000 | 261,621 | ||
| total current liabilities | 8,008,000 | 9,032,000 | 6,740,000 | 7,210,000 | 8,597,000 | 7,811,000 | 7,126,000 | 4,474,000 | 4,118,000 | 4,339,700 | 4,872,152 | 3,397,315 |
| lease obligations | 1,657,000 | 1,814,000 | 1,073,000 | 781,000 | 941,000 | 1,097,000 | 1,058,000 | 1,184,000 | 855,000 | 964,191 | 1,069,687 | 886,956 |
| deferred tax liabilities | 955,000 | 1,138,000 | 998,000 | 1,245,000 | 1,245,000 | 1,245,000 | 2,249,000 | 3,048,000 | 3,430,000 | 3,709,312 | ||
| other liabilities | 907,000 | 944,000 | 1,433,000 | 2,181,000 | 1,965,000 | 1,883,000 | 2,872,000 | 391,000 | 391,000 | 360,797 | ||
| total liabilities | 11,806,000 | 13,180,000 | 14,168,000 | 15,299,000 | 16,540,000 | 12,218,000 | 13,518,000 | 9,258,000 | 8,949,000 | 9,513,950 | 5,941,839 | 4,284,271 |
| commitments and contingencies | ||||||||||||
| shareholders’ equity | ||||||||||||
| unlimited common shares, no par value; 979,949,668 issued and outstanding at march 31, 2024 and december 31, 2023 | 380,973,000 | |||||||||||
| additional paid-in capital | 31,030,000 | 29,929,000 | 28,824,000 | 27,156,000 | 25,431,000 | 23,666,000 | 22,227,000 | 13,846,000 | 11,354,000 | 9,313,136 | 6,732,887 | 5,601,641 |
| accumulated deficit | -180,093,000 | -170,933,000 | -148,526,000 | -148,038,000 | -142,789,000 | -136,404,000 | -133,597,000 | -128,601,000 | -123,328,000 | -119,391,398 | -116,101,406 | -109,755,719 |
| accumulated comprehensive income | -15,000 | 48,000 | -843,000 | 13,000 | 53,000 | |||||||
| total shareholders' equity | 231,895,000 | 240,017,000 | 260,884,000 | 259,479,000 | 263,058,000 | 267,392,000 | 268,781,000 | 266,220,000 | 269,041,000 | 270,885,343 | 271,560,312 | 276,068,013 |
| total liabilities and shareholders’ equity | 243,701,000 | 253,197,000 | 275,052,000 | 274,778,000 | 279,598,000 | 279,610,000 | 282,299,000 | 275,478,000 | 277,990,000 | |||
| construction in progress | ||||||||||||
| unlimited common shares, no par value; 979,949,668 issued and outstanding at december 31, 2023 and december 31, 2022 | 380,973,000 | |||||||||||
| liability due to qorvo | 3,654,000 | 3,591,000 | 3,529,000 | |||||||||
| unlimited common shares, no par value; 979,949,668 issued and outstanding at september 30, 2023 and december 31, 2022 | 380,973,000 | |||||||||||
| accumulated comprehensive loss | -387,000 | -612,000 | -557,000 | |||||||||
| unlimited common shares, no par value; 979,949,668 issued and outstanding at june 30, 2023 and december 31, 2022 | 380,973,000 | |||||||||||
| unlimited common shares, no par value; 979,949,668 issued and outstanding at march 31, 2023 and december 31, 2022 | 380,973,000 | |||||||||||
| unlimited common shares, no par value; 979,949,668 and 979,899,668 issued and outstanding at december 31, 2022 and december 31, 2021 | 380,973,000 | |||||||||||
| unlimited common shares, no par value; 979,949,668 and 979,899,668 issued and outstanding at september 30, 2022 and december 31, 2021 | 380,973,000 | |||||||||||
| accumulated comprehensive | -822,000 | |||||||||||
| assets in process | ||||||||||||
| debt security | 1,000,000 | |||||||||||
| unlimited common shares, no par value; 979,899,668 issued and outstanding at june 30, 2022 and december 31, 2021 | 380,962,000 | |||||||||||
| unlimited common shares, no par value; 979,899,668 issued and outstanding at march 31, 2022 and december 31, 2021 | ||||||||||||
| current assets: | ||||||||||||
| liabilities, mezzanine and shareholders' equity | ||||||||||||
| current liabilities: | ||||||||||||
| current portion of debt obligation | ||||||||||||
| mezzanine equity: | ||||||||||||
| series 1 preferred shares, without par value; 20 shares authorized 0 and 12 series 1 issued and outstanding at december 31, 2021 and december 31, 2020, respectively | ||||||||||||
| shareholders' equity: | ||||||||||||
| unlimited common shares without par value; 979,899,668 and 642,036,228 issued and outstanding at december 31, 2021 and december 31, 2020, respectively | 380,961,940 | |||||||||||
| common stock subscribed | ||||||||||||
| accumulated other comprehensive income | 1,665 | |||||||||||
| total liabilities and equity | 280,399,293 | |||||||||||
| current portion of debt obligations | ||||||||||||
| series 1 preferred shares, no par value; | ||||||||||||
| 20 shares authorized | ||||||||||||
| 0 and 12 series 1 preferred shares issued and outstanding | ||||||||||||
| at september 30, 2021 and december 31, 2020, respectively | ||||||||||||
| shareholders' equity | ||||||||||||
| unlimited common shares, no par value; | ||||||||||||
| 979,738,168 and 642,036,228 issued and outstanding | 380,928,831 | |||||||||||
| common shares subscribed | ||||||||||||
| total liabilities, mezzanine equity and shareholders' equity | 277,502,151 | 280,352,284 | ||||||||||
| series 1 preferred shares, no par value; 20 shares authorized 0 and 12 series 1 preferred shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively | ||||||||||||
| unlimited common shares, no par value; 977,950,993 and 642,036,228 issued and outstanding at june 30, 2021 and december 31, 2020, respectively | 380,222,091 |
We provide you with 20 years of balance sheets for Zomedica Corp stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Zomedica Corp. Explore the full financial landscape of Zomedica Corp stock with our expertly curated balance sheets.
The information provided in this report about Zomedica Corp stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.